NCT02267434View on ClinicalTrials.gov

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Parkinson DiseaseNeurodegenerative Diseases
Interventions
BIOLOGICAL

Low dose AFFITOPE® PD03A + Adjuvant

s.c. injection

BIOLOGICAL

High dose AFFITOPE® PD03A + Adjuvant

s.c. injection

BIOLOGICAL

Adjuvant without active component

s.c. injection

Trial Locations (2)

1080

Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität -Privatklinik Josefstadt, Vienna

6020

Medical University Innsbruck, Department of Neurology, Innsbruck

All Listed Sponsors
collaborator

PROSENEX AmbulatoriumbetriebsGMBH

UNKNOWN

collaborator

Medical University Innsbruck

OTHER

collaborator

Forschungszentrum Juelich

OTHER

lead

Affiris AG

INDUSTRY

NCT02267434 - Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease | Biotech Hunter | Biotech Hunter